No Data
Asia Investment Research Memo (2): For the first half of the fiscal year ending March 2025, the loss margin has narrowed. Stocks and project sales are pushed to the second half.
■Overview of Japan Asia Investment <8518> Financial Results 1. Overview of the first half of the fiscal year ending March 2025 The performance for the first half of the fiscal year ending March 2025 (on a fund consolidated basis) shows operating revenue of 1,432 million yen, an increase of 12.9% year-on-year, and operating profit of 68 million yen (compared to a loss of 239 million yen in the previous year). Under the conventional consolidated basis, operating revenue increased by 55.8% year-on-year to 664 million yen, while operating loss was 61 million yen (compared to a loss of 535 million yen in the previous year) and ordinary loss was 64 million yen (the same as 558...
Overview of the Tokyo Stock Exchange Growth Market 250 Index Futures: Slight decline continues, but downside is limited.
On December 11, the Futures for the Tokyo Stock Exchange Growth Market 250 Index was down 4 points from the previous trading day at 637 points. The high was 642 points, the low was 636 points, and the intraday trading volume was 2,274 contracts. On the previous day, December 10, the Dow Inc. in the USA fell for the fourth consecutive day. Trading was mixed due to a lack of materials, and after the opening, it was uneven. The Dow was pressured by selling due to concerns over high prices and remained weak throughout the day. The Nasdaq was temporarily boosted by a rise in Alphabet (GOOG), but selling due to aversion to high interest rates, along with Oracle Corp.
Stock blogger Sana Sae: Thoroughly scrutinize trend themes if hosting an ipos festival! My focus stock is... [FISCO Social Reporter]
The following is a comment written by the individual investor "Sanasae" (blog: 'Sanasae's Beautiful Investment Life'), who is a Fisco Social Reporter. At Fisco, we are committed to collaborating with individuals who actively share information to provide a wider range of information to investors.-----------*Written on December 4, 2024, at 11 AM. Hello everyone, good evening. Finally, the market that seems to excite individual investors has arrived. Yes, it's the end-of-year 'ipos festival.'
Announcement of a briefing session for institutions
Thank you very much for your continued support of our company. A briefing session will be held jointly by the GN Group and Gyre Therapeutics for institutions. - Date and time: December 23, 2024 (Monday) - Speakers: Tomoya Kitagawa, Executive Director and CFO of our company, and Ruoyu Chen, CFO of Gyre Therapeutics - Target audience: Institutions If there are any undisclosed facts, please be aware.
The Tokyo Stock Exchange Growth Index rebounded slightly, and after the buying subsided, it entered a phase of consolidation.
TSE Growth Market Index 816.55 +0.35 / volume 0.1 billion 69.42 million shares / trading value 106.9 billion yen TSE Growth Market 250 Index 638.72 +0.64 / volume 86.13 million shares / trading value 75.7 billion yen Today's growth market saw a slight rebound in the TSE Growth Market Index and the TSE Growth Market 250 Index, with 234 stocks gaining, 322 losing, and 37 unchanged. The growth market today faced heavy resistance on the upside. The previous day's U.S. market was stable.
Recent questions received and their answers.
Thank you for your continued support of our business. We would like to disclose the questions received from investors and their corresponding answers as follows. This disclosure is made to strengthen information dissemination and from the perspective of fair disclosure. Q: The stock price of our major listed subsidiary, Gyre Therapeutics (hereinafter "GYRE"), has dropped significantly. Was there any issue with the clinical trial results of F351?